Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03445013 · ClinicalTrials.gov registry record · Phase 1
A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis
A Phase 1 study, sponsored by Novan.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT03445013 is a Phase 1 study that has completed, run by Novan. The registered enrollment target is 36 participants.
The verdict
NCT03445013, a Phase 1 study, has completed, sponsored by Novan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The objectives of this study are to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of SB414 in subjects with mild to moderate plaque psoriasis.
Interventions
- DRUG Vehicle
- DRUG SB414 6%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2017-10-13 |
| Est. Completion | 2018-02-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03445013
The ClinicalTrials.gov registry entry for NCT03445013 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novan, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT03445013 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03445013 about?
NCT03445013 is a clinical study titled "A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis". The objectives of this study are to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of SB414 in subjects with mild to moderate plaque psoriasis.
What is the current status of trial NCT03445013?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2017-10-13. Estimated completion is 2018-02-06.
What interventions are being tested in trial NCT03445013?
The interventions under investigation include: Vehicle (DRUG), SB414 6% (DRUG).
Who is sponsoring clinical trial NCT03445013?
This trial is sponsored by Novan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.